Intra-Cellular Therapies’ (ITCI) Neutral Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their neutral rating on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a research note published on Wednesday,Benzinga reports. The firm currently has a $132.00 price target on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently commented on ITCI. Baird R W downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Mizuho cut shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $140.00 to $132.00 in a report on Monday, February 24th. Royal Bank of Canada restated a “sector perform” rating and issued a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Eleven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $106.23.

Intra-Cellular Therapies Price Performance

Shares of Intra-Cellular Therapies stock opened at $131.87 on Wednesday. The firm has a market cap of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies has a 52-week low of $64.09 and a 52-week high of $131.98. The company’s 50-day simple moving average is $129.62 and its 200-day simple moving average is $101.43.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The business had revenue of $199.22 million during the quarter, compared to analysts’ expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. Equities research analysts anticipate that Intra-Cellular Therapies will post -0.64 EPS for the current year.

Institutional Trading of Intra-Cellular Therapies

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Intra-Cellular Therapies by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 9,721,360 shares of the biopharmaceutical company’s stock worth $811,928,000 after purchasing an additional 93,107 shares during the period. Norges Bank acquired a new stake in Intra-Cellular Therapies in the 4th quarter worth about $268,347,000. Invesco Ltd. grew its holdings in Intra-Cellular Therapies by 2.9% in the 4th quarter. Invesco Ltd. now owns 3,077,174 shares of the biopharmaceutical company’s stock valued at $257,006,000 after buying an additional 87,582 shares during the period. Deep Track Capital LP increased its stake in shares of Intra-Cellular Therapies by 24.9% during the 4th quarter. Deep Track Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock valued at $167,040,000 after acquiring an additional 399,307 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of Intra-Cellular Therapies by 3.1% during the 3rd quarter. State Street Corp now owns 1,858,915 shares of the biopharmaceutical company’s stock worth $136,017,000 after acquiring an additional 56,664 shares during the period. Institutional investors and hedge funds own 92.33% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.